このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Arbutus Biopharma マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
Mike McElhaugh
最高経営責任者
US$1.6m
報酬総額
| CEO給与比率 | 29.8% |
| CEO在任期間 | 1.6yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 2.8yrs |
| 取締役会の平均在任期間 | 5.7yrs |
経営陣の近況
Recent updates
Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$74m |
| Dec 31 2023 | US$2m | US$483k | -US$73m |
| Sep 30 2023 | n/a | n/a | -US$75m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$70m |
| Dec 31 2022 | US$1m | US$449k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | n/a | n/a | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$87m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$1m | US$415k | -US$76m |
報酬と市場: Mikeの 総報酬 ($USD 1.62M ) は、 US市場 ($USD 2.45M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Mikeの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Mike McElhaugh (50 yo)
1.6yrs
在職期間
US$1,620,485
報酬
Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 1.6yrs | US$1.62m | データなし | |
| Chief Scientific Officer | 9.4yrs | US$1.61m | 0.79% $ 4.6m | |
| CFO & Chief Accounting Officer | 6yrs | US$1.46m | 0.0089% $ 51.4k | |
| Vice President of Investor Relations | 2.8yrs | データなし | データなし | |
| General Counsel | less than a year | データなし | データなし | |
| Vice President of Human Resources | no data | データなし | データなし | |
| Chief Medical Officer | less than a year | データなし | 0.0028% $ 16.2k | |
| Corporate Secretary | 14.1yrs | データなし | データなし |
2.8yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: ABUSの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | less than a year | US$1.62m | データなし | |
| Independent Non-Executive Director | 9.5yrs | US$174.24k | 0.00053% $ 3.1k | |
| Independent Director | 7.3yrs | US$161.74k | 0% $ 0 | |
| Independent Non-Executive Director | 9.3yrs | US$156.74k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.7yrs | US$176.74k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 5.7yrs | データなし | 0% $ 0 | |
| Independent Chairman of the Board of Directors | 5.6yrs | US$187.99k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし |
5.7yrs
平均在職期間
57.5yo
平均年齢
経験豊富なボード: ABUSの 取締役会 は 経験豊富 であると考えられます ( 5.7年の平均在任期間)。